23 October 2014 - United States-based Iroko Pharmaceuticals has signed a licensing agreement with Landsteiner Scientific, a company engaged in the research and development, manufacture, distribution, and marketing of healthcare products.

It was revealed today that the contract has been signed for the exclusive rights to market and sell Zorvolex (diclofenac) capsules in Mexico.

According to the agreement, Landsteiner Scientific will be responsible for securing regulatory and pricing approval and for the marketing and distribution of the drug. The product has been approved by the US Food and Drug Administration for the management of mild to moderate acute pain and osteoarthritis pain.